Q&A with Genentech CEO Alexander Hardy on Medicare's drug price negotiations
Before and after it was acquired by Roche, Genentech has made a name for itself with biologics — the large molecules that Congress recently afforded 13 years of protection before new price negotiations can kick in from Medicare.
The expanse of those negotiations, and how they’re about to be implemented, is of paramount focus for biopharma executives looking to shape any changes and stay ahead of the shifting landscape. Genentech CEO Alexander Hardy spoke to Endpoints News late last week about everything from how he sees the new law hitting his company to what he’s telling Congress. See below a slightly shortened transcript of our Q&A.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
